Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab Plus Platinum-Doublet Chemotherapy in Locally Advanced NSCLC
NCT04606303Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2020
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Status: unknown.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04606303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04606303.